Objective: To examine the association between schizophrenia and the quality of care and clinical outcomes of chronic obstructive pulmonary disease (COPD). Design: A Danish nationwide population-based cohort study using comprehensive information from Danish registries between 2008 and 2013. Setting: Public Danish hospitals. Participants: 72 692 COPD patients with hospital contacts including 621 with schizophrenia. Intervention: COPD care. Main Outcome Measures: The quality of COPD care was defined as meeting guideline-recommended process performance measures of care. Potential predictors of COPD care among patients with schizophrenia included patient-(sex, age, alcohol or drug abuse, Global Assessment of Functioning score, duration of schizophrenia), provider-(quality of schizophrenia care), and system-related factors (contact-volume defined as hospital department and clinics' annual average contact volume of COPD patients). Clinical outcomes included 30-day all-cause readmission and 30-day all-cause mortality risk following an admission for exacerbation of COPD. Results: Compared to COPD patients without schizophrenia, COPD patients with schizophrenia had a lower chance of receiving treatment with long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) (Relative risk (RR) 0.92, 95% CI: 0.87-0.98). Female sex was associated with a higher chance of receiving LAMA/LABA treatment among COPD patients with schizophrenia. COPD patients with schizophrenia had a higher risk of 30-day mortality (adjusted odds ratio (OR) 1.27, 95% CI: 1.01-1.59) but not a higher risk of readmission compared with COPD patients without schizophrenia. Conclusions: COPD patients with schizophrenia had a slightly lower chance of receiving LAMA/ LABA treatment, but a substantially increased risk of death following admission for an exacerbation compared with patients without schizophrenia.
Introduction
Schizophrenia is associated with excessive mortality, which corresponds to a 10-20 years reduced life expectancy [1] [2] [3] [4] [5] . Although intentional self-harm partly explain the premature death, mostly is due to chronic medical comorbidities [2, 3, 5] . Patients with schizophrenia have particularly high rates of chronic obstructive pulmonary disease (COPD) compared to the general population [5, 6] , emphasizing the crucial role of early diagnosis, delaying the progression of disease and preventing exacerbations in this vulnerable population. Nevertheless, there is a paucity of population-based data elucidating whether patients with schizophrenia receive adequate COPD care. Moreover, the impact of schizophrenia on clinical outcomes of COPD remains elusive. A Danish nationwide multidisciplinary initiative has routinely collected data on COPD and schizophrenia care on all patients for more than a decade in a public and mainly tax-financed health care system. The universal health coverage provides all Danish citizens regardless of their socioeconomic status free and equal access to care at public hospitals [7, 8] . This setting creates an ideal opportunity to examine whether patients with schizophrenia receive sufficient COPD care and if not, whether specific factors predict potential quality gaps in this population. Moreover, it is possible to explore potential differences in clinical outcomes of COPD in patients with and without schizophrenia. We therefore conducted a nationwide population-based cohort study to: (i) examine the quality of COPD care as reflected by meeting specific process performance measures of care among COPD patients with and without schizophrenia; (ii) identify potential patient-, provider-and health care system-related predictors of quality of COPD care among COPD patients with schizophrenia; (iii) compare 30-day readmission and 30-day mortality risk following an admission for exacerbation of COPD among COPD patients with and without schizophrenia.
Methods
In Denmark, a unique, ten-digit civil registration number is assigned to all residents. The number is used when each contact with the health care system is recorded in public registries and ensures unambiguous individual level linkage of information across data sources [9] . This study was based on data from the following nationwide, populationbased registries: the Danish Clinical Registries (the Danish Schizophrenia Registry (DSR) and the Danish Registry for COPD (DrCOPD)), the Danish National Patient Register (DNPR), the Danish Psychiatric Central Research Register (PCRR) and the Danish Civil Registration System (CRS) [9] [10] [11] [12] [13] [14] [15] [16] [17] . All Danish public hospitals are obliged to report to these registries.
The Danish Clinical Registries
In 2000, a nationwide Danish multidisciplinary initiative was launched in order to monitor and improve the quality of care provided by the Danish health care system. During subsequent years, population-based clinical registries were established to document the care for specific and important diseases including schizophrenia (DSR) and COPD (DrCOPD). These registries contain clinical data and information on delivery of disease-specific performance measures of care in accordance with national clinical guidelines [7, [10] [11] [12] [13] . Multidisciplinary expert panels representing national scientific societies and professional organizations identified the performance measures and relevant prognostic factors to be collected in the registries. The registries have a high coverage including records for 93% of all hospital inpatients and 92% of all hospital outpatients with schizophrenia in the Danish health care system. Since 2004, most patients with schizophrenia who have received treatment in the secondary health care system can thus be identified from the DSR. The data in the registry are prospectively collected using standardized registration forms with comprehensive instructions. The registration form is completed at the time of discharge from a psychiatric hospital for inpatients with schizophrenia and once a year for outpatients with schizophrenia followed at hospital outpatient clinics [10, 11] . The DrCOPD has been operative from 2008 onwards and the COPD diagnosis has been reported to have a positive predictive value of 92% for hospital inpatients and 86 % for hospital outpatients in DrCOPD [12, 13, 15] . In this registry, the quality of care data are prospectively recorded at the time of discharge, hospital transmission or death for inpatients with COPD and as part of everyday clinical routine for outpatients with COPD visiting a hospital outpatient clinic. Although outpatient data can also be obtained from general practitioners, the data coverage remains currently low. All data in the DrCOPD are exclusively reported through codes for clinical procedures and diagnosis codes in the DNPR [12] [13] [14] .
The DNPR
The DNPR has collected information on every Danish inpatient hospital contact since 1977 as well as outpatient-, emergency roomand psychiatric hospital contacts since 1995 [14] . Data records include dates of hospital contact, specific place of treatment, diagnosis of the patient and performed clinical procedures.
The PCRR
The PCRR has recorded all psychiatric diagnoses and contacts in the Danish psychiatric hospitals including dates of admission and discharge since 1969 as well as start and end of hospital outpatient contacts and emergency room visits since 1995 [16, 17] .
The CRS
Since 1969, the CRS has maintained daily updated information on vital status on every Danish citizen [9] .
Study population of patients with COPD
The study population included all in-and outpatients (≥30 years old) treated for acute COPD exacerbation or COPD at any hospital department and outpatient clinic and recorded in the DrCOPD between 1 January 2008 and 31 December 2013. All COPD contacts for each in-and outpatient were included. The DrCOPD includes the following ICD-10 codes for inpatients: DJ44.X as a primary diagnosis or DJ96.X or DJ13.X-DJ18.X as a primary diagnosis in combination with DJ44.X as a secondary diagnosis. For outpatients, the DrCOPD includes DJ44.X or DJ96.X in combination with DJ44.X as a secondary diagnosis [18] .
Patients with schizophrenia
By linkage with the DSR, all COPD in-and outpatients with schizophrenia were identified. Schizophrenia was defined as a recording in the DSR (ICD-10 codes: F20.0-F20.99) as either in-or outpatient with schizophrenia between 1 January 2004, and 31 December 2011. Patients were excluded if schizophrenia was not recorded before their first COPD contact (N = 16), or if they had >5 years between the recording for schizophrenia in the DSR and the subsequent registration in DrCOPD (N = 36). Total 72 692 COPD patients with 211 868 COPD contacts were included in the study, of which 621 (0.85%) COPD patients with 1502 COPD contacts had comorbid schizophrenia.
Predictors of COPD care
Patient-, provider-, and health care system-related factors considered potential predictors of the quality of COPD care among COPD patients with schizophrenia were identified. The patient-related predictors were collected from the DrCOPD, DSR and PCRR and included sex, age, duration of schizophrenia at the time of the hospital contact for COPD, drug (illegal drugs, benzodiazepines or central stimulants) or alcohol abuse and the Global Assessment of Functioning (GAF) score to evaluate the psychosocial functioning of patients with schizophrenia ranging from 1 to 100 [10, 12, 13, 16] . To examine whether a deficient quality of schizophrenia care may potentially be associated with a subsequent inadequate quality of COPD care, the provider-related predictor involved the quality of schizophrenia care preceding the COPD contact. Table 1 lists the 12 assessed process performance measures of care drawn from the DSR and relevant for hospital in-and outpatients with schizophrenia, including incident patients defined as patients who had been diagnosed with schizophrenia within the preceding year [10] . The quality of schizophrenia care was summarized overall by dividing the number of received process performance measures of schizophrenia care with the number of relevant measures for each patient. Patients who received ≥80% of the relevant measures were defined as meeting a high overall quality of schizophrenia care. Contact volume, defined as the average number of COPD contacts in each hospital 
Quality of COPD care
The quality of COPD care was defined as the adherence to ten individual process performance measures of care, relevant to outpatients only and obtained from the DrCOPD [12, 13] (Table 1) . We further summarized the quality of COPD care using an overall composite measure estimated by dividing the number of received process performance measures with the number of relevant measures for the individual patient.
Clinical outcomes of COPD
From the DrCOPD and CRS, we collected information on clinical outcomes of COPD including 30-day all-cause readmission and 30-day all-cause mortality following an admission for exacerbation of COPD [9, 12, 13] (Table 1) .
Statistical analyses
Binary regression was used to estimate the relative risk (RR) of the adherence to the ten individual process performance measures of COPD care and the overall composite measure of quality of COPD care among COPD patients with and without schizophrenia. Meeting ≥80% of the relevant process performance measures were defined as a high overall quality of COPD care. We further repeated the analysis using alternative thresholds ranging from 60% to 90% to examine the robustness of our findings. All analysis were stratified according to sex, age and dyspnea using the Medical Research Council (MRC) scale. Binary regression was used to examine the association between patient-, provider-and health care systemrelated predictors and the quality of COPD care among COPD patients with schizophrenia. Sex, age, abuse, GAF score, duration of schizophrenia, quality of schizophrenia care and contact volume were examined as potential predictors. We only included predictors in the mutually adjusted multivariable analysis that were statistical significantly associated with the quality of COPD care in the univariable analysis. Logistic regression was used to calculate the odds ratio (OR) for 30-day readmission and 30-day mortality. To control for confounding, OR's were adjusted for age, sex and Charlson Index. All 95% confidence intervals (CI) in the study were corrected for clustering of COPD patients within the hospital departments and outpatient clinics using robust estimates of the variance. A two sided P-value ≤ 0.05 was considered to be significant. STATA (version 11.2 Special Edition) was used for all analyses.
Results
Compared to COPD patients without schizophrenia, COPD patients with schizophrenia were younger, had a higher body mass index (BMI) and were more likely to be smokers and inpatients admitted for acute COPD exacerbation. The majority of both COPD outpatients with and without schizophrenia received 80-100% of all relevant process performance measures of COPD care (Table 2) . COPD patients with schizophrenia were less likely to receive treatment with long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) (RR 0.92, 95% CI: 0.87-0.98) compared to those without schizophrenia (Table 3) . We found no clear association for the remaining measures and no evidence of systematic interaction when stratifying all analysis according to sex, age and the MRC scale (data not shown). In adjusted models, female sex was associated with a higher chance of receiving treatment with LAMA/LABA (RR 1.19, 95% CI: 1.02-1.39) ( Table 4) . None of the other examined factors were independently associated with the chance of meeting LAMA/LABA medication. In addition, we found no independent association between potential predictors of COPD care and the remaining COPD process performance measures (data not shown). 
Discussion
We found that COPD patients with schizophrenia had a lower chance of receiving maintenance treatment with LAMA/LABA. The lower chance of receiving LAMA/LABA treatment was in particular seen for male patients with schizophrenia. COPD patients with schizophrenia had a substantially higher adjusted risk of 30-day mortality following hospital admission for an exacerbation compared to COPD patients without schizophrenia, but no increased risk of early readmission.
Study strengths and limitations
The study has several strengths including a large study size, the nationwide design, the inclusion of all COPD hospital contacts and the comprehensive data collection of the quality of COPD care. In general, Danish registries record information of high quality as extensive efforts are made to ensure validity and completeness of data [9] [10] [11] [12] [13] [14] [15] [16] [17] . Detailed instructions for the data collection in standardized registration forms secure data uniformity and accuracy in the DSR whilst validation studies have assessed large nationwide samples of COPD codes in the DrCOPD against hospital medical records. Structured audits are likewise conducted on a national, regional and local basis to provide continuous feedback to clinicians in hospitals for both the DSR and DrCOPD [10] [11] [12] [13] 15] . A limited set of variables are obtainable from the DSR and DrCOPD to ensure high validity rather than extensive datasets with potential insufficient data quality and completeness. Unmeasured factors may consequently potentially influence the quality of COPD care. The examined performance measures were, however, considered relevant for all included patients despite characteristics, psychiatric disease and the treating hospital, which reduces the risk of confounding. Only hospital in-and outpatients treated for acute COPD exacerbation or COPD were included in the study. Therefore, the quality of COPD care remains unknown for COPD patients with schizophrenia exclusively seen at the GPs. The interpretation of the results should moreover be considered with the notion that patients with schizophrenia are potentially more likely to be undiagnosed or untreated for their COPD comorbidity.
Comparison with other studies
To our knowledge, no previous studies have examined the quality of COPD care for patients with and without schizophrenia. However, there are previous studies, which have reported less intensive preventive care among psychiatric compared to non-psychiatric patients in general, including lower chance of asking the patient about smoking status and less use of smoking cessation interventions and recording of BMI [19] [20] [21] [22] . The magnitude of these differences, however, varies considerably whilst some studies found no such shortfall in the preventive care [19] . In addition, U.S studies within cardiovascular care have reported that patients with mental illness are more likely to be admitted to low-quality somatic hospitals and receive treatment by low-quality cardiac surgeons for cardiovascular comorbidities [23] [24] [25] . Differences in organization and financing may, however, complicate the generalizability of such findings across health care systems. A previous Danish nationwide study has reported an association between serious mental illness and increased risk of 30-day readmission for ambulatory care-sensitive conditions including COPD/adult asthma exacerbation [26] . An association which we could not confirm in our study. In contrast, our finding on a higher 30-day mortality is at least in accordance with another population-based Danish study, which found that patients with a severe mental illness had a higher risk of 30-day mortality after hospitalization for an infection including pneumonia compared to patients without a severe mental illness [27] .
In the current study, we demonstrated that the majority of COPD patients with schizophrenia were smokers and had a higher BMI in spite of a younger age. These characteristics indicate a possible inadequate preventive medical service. Moreover, we found that COPD patients with schizophrenia were less likely to receive the recommended LAMA/LABA treatment, even in a universal health care system with equity as a stated priority. The explanation of the results may involve difficulties with medication adherence due to cognitive impairment in patients with schizophrenia or inadequate availability and quality of medical advice. The remaining explored COPD process performance measures were equally distributed among COPD patients with and without schizophrenia. Among COPD patients with schizophrenia, we were only able to identify female sex as an independent predictor of receiving LAMA/ LABA despite examining a broad panel of patient-, provider-and health care system-related factors as potential predictors of COPD care. The found association may reflect that men may lack the attention, energy or willingness to attend regularly follow up checks and hence not receive the recommended pharmacological therapy. The higher risk of 30-day mortality following an admission for exacerbation of COPD among patients with schizophrenia may be attributed to a combination of more severe exacerbation and stage of disease (which we attempted to account for in the analysis) and potentially insufficient follow up checks by the outpatient clinics or GPs after discharge. The fact that we did not find an increase in the risk of early readmission among patients with schizophrenia despite the increased early mortality indicate that deficiency in post-discharge care may be an important factor to address when aiming to improve the survival of COPD patients with schizophrenia. The results further underscore the need to focus interventions on prophylactic care, delaying the progression of COPD and preventing exacerbations to reduce the excess mortality. Several additional complex factors of which we can only speculate may influence the quality and predictors of care as well as clinical outcomes of COPD. For COPD patients with schizophrenia, lack of energy to manage a physical comorbidity concurrent with the mental illness, cognitive disability, transportation problems or difficulties navigating between the somatic and psychiatric health care system may constitute challenges. Mistrust, lack of information and a problematic relationship with the physician may also cause disengagement. Physician barriers may involve discrimination, stigmatization and lack of experience with mental illness whilst resource and time constraints may influence disparities as system factors. To assist future COPD patients with schizophrenia, care approaches that optimize social support, stress management, communication with providers including acceptable, accessible and flexible services with engaged and caring physicians, and reduce compartmentalization of medical and psychiatric care have been identified to potentially increase the patient's engagement in care and management of a medical comorbidity [28] [29] [30] . We encourage further efforts in order to address the increased early mortality experienced by patients with schizophrenia after discharge with COPD.
Conclusion
In conclusion, this nationwide population-based cohort study demonstrated that patients with schizophrenia in general appeared to receive COPD care, which was comparable to that of patients without schizophrenia, except for a lower chance of receiving maintenance treatment with LAMA/LABA. However, patients with schizophrenia experienced a higher 30-day mortality following an admission for exacerbation of COPD without an increased risk of early readmission, which indicates that more efforts are warranted to improve the clinical outcome for COPD patients with schizophrenia.
